This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Duearity Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Duearity's earnings have been declining at an average annual rate of -32.4%, while the Medical Equipment industry saw earnings growing at 17.9% annually. Revenues have been growing at an average rate of 111.5% per year.
Belangrijke informatie
-32.4%
Groei van de winst
12.9%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 6.2% |
| Inkomstengroei | 111.5% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -1,812.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Duearity geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -30 | 27 | 0 |
| 31 Mar 24 | 2 | -30 | 26 | 0 |
| 31 Dec 23 | 2 | -26 | 21 | 0 |
| 30 Sep 23 | 1 | -21 | 13 | 0 |
| 30 Jun 23 | 1 | -17 | 11 | 0 |
| 31 Mar 23 | 1 | -17 | 11 | 0 |
| 31 Dec 22 | 0 | -19 | 13 | 0 |
| 30 Sep 22 | 0 | -20 | 21 | 0 |
| 30 Jun 22 | 0 | -20 | 19 | 0 |
| 31 Mar 22 | 0 | -18 | 9 | 0 |
| 31 Dec 21 | 0 | -15 | 7 | 0 |
| 31 Dec 20 | 0 | -2 | 2 | 0 |
Kwaliteitswinsten: DEAR is currently unprofitable.
Groeiende winstmarge: DEAR is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DEAR is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Versnelling van de groei: Unable to compare DEAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: DEAR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.4%).
Rendement op eigen vermogen
Hoge ROE: DEAR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.